Evidence map›Paper›PMID 31941448›Full record

ArticleBMC infectious diseases2020

Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration.

Housseini Dolo, Yaya Ibrahim Coulibaly, Fatoumata Nene Konipo, Siaka Yamoussa Coulibaly, Salif Seriba Doumbia, Moussa Brema Sangare, Lamine Soumaoro, Michel Emmanuel Coulibaly, Abdallah Amadou Diallo, Yaye Diarra and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Housseini DoloFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali. hdolo@icermali.org.ORCID http://orcid.org/0000-0002-4234-3488
Yaya Ibrahim CoulibalyFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Fatoumata Nene KonipoFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Siaka Yamoussa CoulibalyFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Salif Seriba DoumbiaFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Moussa Brema SangareFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Lamine SoumaoroFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Michel Emmanuel CoulibalyFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Abdallah Amadou DialloFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Yaye DiarraFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Modibo SangareFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Seydou DoumbiaFilariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, BP :1805, Point G, Bamako, Mali.
Robert ColebundersGlobal Health Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.
Thomas B NutmanCentre National d'Appui à la lutte contre la Maladie, Bamako, Mali.
University of Bamako · MLUniversity of Antwerp · BECentre Pour le Développement des Vaccins-Mali · MLNational Institutes of Health · US

Funding

Mali International Center for Excellence in Research: FilariasisZIAAI001063 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$3.2M
Training Program on Operational and Health Services Research for Malaria in MaliD43TW008652 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI SEYDOU DOUMBIA, Alexandre Delamou · 2010 to 2026
$3.1M
Mali International Center for Excellence in Research: FilariasisZ01AI001063 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2008 to 2008
$603k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (US) Z01-AI001063FIC NIH HHS D43 TW008652Intramural NIH HHS Z01 AI001063USAID Global Development Alliance AID-OAA-G-14-000008
6 · The paper itself

Abstract

backgroundLymphedema is a public health problem in countries with lymphatic filariasis (LF) including Mali. We studied the epidemiology and clinical presentation of lymphedema in three previously LF-endemic health districts of Mali after at least five consecutive rounds of mass drug administration (MDA) with albendazole and ivermectin.

methodsFrom 2016 to 2018, we used passive and active case finding methods to identify lymphedema cases in three health districts with high pre-MDA LF prevalence: Kolondieba (66%), Bougouni (44%) and Kolokani (34%).

resultsThree hundred and thirty nine cases of lymphedema were identified, 235 (69.32%) through active case finding. Their median age was 56 years (range 2-90) and 286 (84.36%) were women. Lymphedema was reported in 226 (78.5%) people aged 41 years and older compared to 73 (21.5%) people below the age of 41 years (Chi

conclusionHealth districts in Mali with the highest pre-MDA LF prevalences had the highest prevalence of lymphedema. Efforts to actively identify lymphedema cases should be scaled up in previous LF-endemic areas, and should be supplemented by a morbidity management and disability prevention plan at the peripheral health system level.

Indexed as

Endemic DiseasesMass Drug AdministrationWithholding TreatmentWuchereria bancroftiAdolescentAdultAgedAged, 80 and overAlbendazoleAnimalsChildChild, PreschoolCross-Sectional StudiesElephantiasis, FilarialFemaleHumansAlbendazoleIvermectinActive and passive case detectionClinical investigationDistributionLymphedemaMali

Identifiers

PMID31941448
PMCPMC6964034
OpenAlexW3005117996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.